|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2009-6-22
|
|
pubmed:abstractText |
Approximately 30% of all colorectal cancer (CRC) patients are diagnosed with stage II disease. Adjuvant therapy is not widely recommended. However, it is well established that a subgroup of patients with stage II are at high risk for recurrence within their lifetime and should be considered for adjuvant chemotherapy. The present work was designed to assess the value of group IIA phospholipase A2 (PLA2) as a predictor of disease outcome in stage II CRC patients with long-term follow-up.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1230-5
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19276398-Chemotherapy, Adjuvant,
pubmed-meshheading:19276398-Colorectal Neoplasms,
pubmed-meshheading:19276398-Disease Progression,
pubmed-meshheading:19276398-Disease-Free Survival,
pubmed-meshheading:19276398-Finland,
pubmed-meshheading:19276398-Follow-Up Studies,
pubmed-meshheading:19276398-Group II Phospholipases A2,
pubmed-meshheading:19276398-Humans,
pubmed-meshheading:19276398-Immunohistochemistry,
pubmed-meshheading:19276398-Kaplan-Meier Estimate,
pubmed-meshheading:19276398-Microarray Analysis,
pubmed-meshheading:19276398-Multivariate Analysis,
pubmed-meshheading:19276398-Neoplasm Recurrence, Local,
pubmed-meshheading:19276398-Neoplasm Staging,
pubmed-meshheading:19276398-Predictive Value of Tests,
pubmed-meshheading:19276398-Prognosis,
pubmed-meshheading:19276398-Proportional Hazards Models,
pubmed-meshheading:19276398-Survival Rate,
pubmed-meshheading:19276398-Time Factors,
pubmed-meshheading:19276398-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma.
|
|
pubmed:affiliation |
Department of Oncology and Radiotherapy,Turku University Hospital, University of Turku, Turku, Finland. abuhme@utu.fi
|
|
pubmed:publicationType |
Journal Article
|
